Zydus Lifesciences informed that it has received the establishment inspection report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing facility located in Ambernath, Maharashtra.

The inspection was conducted by the USFDA from February 10 to 14, 2025 and concluded with no observations. The facility has been classified under the no action indicated (NAI) category.

The company reported a 29.62 percent jump in consolidated net profit of INR 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter. [Include Q4 FY 25 results]

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.